Halozyme Therapeutics, Inc. has entered a pivotal global collaboration and non-exclusive licensing agreement with Acumen Pharmaceuticals. This partnership focuses on utilizing Halozyme’s ENHANZE drug delivery technology to potentially transform the administration of Acumen’s Alzheimer’s treatment.

Groundbreaking Approach to Alzheimer’s Treatment Administration

The agreement details include an initial payment by Acumen to Halozyme, alongside the possibility of additional milestone payments that hinge on development, regulatory, and sales benchmarks. Additionally, Halozyme will receive royalties from sales of ENHANZE-enhanced products. This could mark a substantial advancement in treatment options for patients suffering from early Alzheimer’s disease, a condition with a global impact.

Halozyme and Acumen Aim to Redefine Alzheimer’s Disease Therapy

Acumen’s therapeutic candidate, ACU193, is a monoclonal antibody targeting Amyloid-β Oligomers, believed to play a crucial role in early Alzheimer’s disease. Following encouraging Phase 1 trial outcomes, ACU193 has also attained Fast Track status from the FDA, signifying its potential in altering the treatment landscape for early Alzheimer’s.

The President and CEO of Halozyme, Dr. Helen Torley, emphasizes the vision to improve treatments for Alzheimer’s patients. This collaboration underlines the shifting dynamics in Alzheimer’s treatment approaches and Halozyme’s role in fostering innovative delivery methods. With over a dozen collaborations, ENHANZE technology by Halozyme is set to broaden its influence in the therapeutic delivery sector, touching upon more than 60 targets to date.

  ACU193, Acumen Pharmaceuticals, Alzheimer’s Disease, Dr. Helen Torley, Halozyme Therapeutics